Safety Profile of Upadacitinib in Patients at Risk of Cardiovascular Disease: Integrated Post Hoc Analysis of the SELECT Phase III Rheumatoid Arthritis Clinical Programme

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2023 Jun 12

PMID 37308218

Authors

Roy Fleischmann

Jeffrey R Curtis

Christina Charles-Schoeman

Eduardo Mysler

Kunihiro Yamaoka

Christophe Richez

Hannah Palac

Deanne Dilley

Jianzhong Liu

Sander Strengholt

Gerd Burmester

Affiliations

Soon will be listed here.

Abstract

Objective: Increased risk of serious adverse events (AEs) was reported for tofacitinib relative to tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis (RA) aged ≥50 years enriched for cardiovascular (CV) risk (ORAL Surveillance). We assessed post hoc the potential risk of upadacitinib in a similar RA population.

Methods: Pooled safety data from six phase III trials were evaluated post hoc for AEs in patients receiving upadacitinib 15 mg once a day (with or without conventional synthetic disease-modifying antirheumatic drugs), adalimumab 40 mg every other week with concomitant methotrexate (MTX), or MTX monotherapy in the overall trial population and in a subset of patients with higher CV risk (aged ≥50 years, ≥1 CV risk factor). Higher-risk patients from a head-to-head study of upadacitinib 15 mg versus adalimumab (SELECT-COMPARE) were assessed in parallel. Exposure-adjusted incidence rates for treatment-emergent AEs were summarised based on exposure to upadacitinib or comparators.

Results: A total of 3209 patients received upadacitinib 15 mg, 579 received adalimumab and 314 received MTX monotherapy; ~54% of the patients were included in the overall and SELECT-COMPARE higher-risk populations. Major adverse cardiovascular events (MACE), malignancy (excluding non-melanoma skin cancer (NMSC)) and venous thromboembolism (VTE) were more frequent in the higher-risk cohorts versus the overall population but were generally similar across treatment groups. Rates of serious infections in higher-risk populations and herpes zoster (HZ) and NMSC in all populations were higher with upadacitinib 15 mg than comparators.

Conclusions: An increased risk of MACE, malignancy (excluding NMSC) and VTE was observed in higher-risk populations with RA, yet risk was comparable between upadacitinib-treated and adalimumab-treated patients. Higher rates of NMSC and HZ were observed with upadacitinib versus comparators across all populations, and increased rates of serious infections were detected in upadacitinib-treated patients at higher CV risk.

Trial Registration Numbers: NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343.

Citing Articles

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.

Baraliakos X, van der Heijde D, Sieper J, Inman R, Kameda H, Maksymowych W Arthritis Res Ther. 2024; 26(1):197.

PMID: 39533349 PMC: 11556075. DOI: 10.1186/s13075-024-03412-8.

Herpes Zoster and Venous Thromboembolism Following Upadacitinib Treatment for Severe Atopic Dermatitis.

Cael Aoki K, Burnette C, Bartos S Cureus. 2024; 16(10):e71007.

PMID: 39507180 PMC: 11539937. DOI: 10.7759/cureus.71007.

Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease.

Ma C, Jairath V, Feagan B, Peyrin-Biroulet L, Danese S, Sands B Nat Rev Gastroenterol Hepatol. 2024; 21(11):792-808.

PMID: 39379665 DOI: 10.1038/s41575-024-00989-y.

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.

van Vollenhoven R, Hall S, Wells A, Meerwein S, Song Y, Tanjinatus O RMD Open. 2024; 10(3.

PMID: 39053948 PMC: 11284904. DOI: 10.1136/rmdopen-2023-004037.

Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.

Chen P, Chang S, Chen Y, Chen H, Huang P, Huang C Clin Rheumatol. 2024; 43(8):2503-2511.

PMID: 38954278 DOI: 10.1007/s10067-024-07041-z.

References

Tanaka Y . A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020; 30(5):779-787. DOI: 10.1080/14397595.2020.1782049. View

Burmester G, Kremer J, Van den Bosch F, Kivitz A, Bessette L, Li Y . Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391(10139):2503-2512. DOI: 10.1016/S0140-6736(18)31115-2. View

Liu C, Kieltyka J, Fleischmann R, Gadina M, OShea J . A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. Arthritis Rheumatol. 2021; 73(12):2166-2178. PMC: 8671145. DOI: 10.1002/art.41906. View

Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H . Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020; 79(11):1400-1413. PMC: 7569391. DOI: 10.1136/annrheumdis-2019-216761. View

Cho S, Lee J, Han M, Bae S, Sung Y . The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs. Arthritis Res Ther. 2017; 19(1):277. PMC: 5732524. DOI: 10.1186/s13075-017-1482-y. View

Rodgers J, Jones J, Bolleddu S, Vanthenapalli S, Rodgers L, Shah K . Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis. 2019; 6(2). PMC: 6616540. DOI: 10.3390/jcdd6020019. View

Smolen J, Pangan A, Emery P, Rigby W, Tanaka Y, Ignacio Vargas J . Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019; 393(10188):2303-2311. DOI: 10.1016/S0140-6736(19)30419-2. View

Burmester G, Cohen S, Winthrop K, Nash P, Irvine A, Deodhar A . Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023; 9(1). PMC: 9923346. DOI: 10.1136/rmdopen-2022-002735. View

Cohen S, van Vollenhoven R, Winthrop K, Zerbini C, Tanaka Y, Bessette L . Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020; 80(3):304-311. PMC: 7892382. DOI: 10.1136/annrheumdis-2020-218510. View

10.

van Vollenhoven R, Tas S, Nurmohamed M . Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry". Ann Rheum Dis. 2021; 82(8):e177. PMC: 10359557. DOI: 10.1136/annrheumdis-2021-221146. View

11.

Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann R, Geissler K . Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2020; 80(1):71-87. PMC: 7788060. DOI: 10.1136/annrheumdis-2020-218398. View

12.

Khosrow-Khavar F, Kim S, Lee H, Lee S, Desai R . Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022; 81(6):798-804. PMC: 9117457. DOI: 10.1136/annrheumdis-2021-221915. View

13.

Myasoedova E, Chandran A, Ilhan B, Major B, Michet C, Matteson E . The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis. 2015; 75(3):560-5. PMC: 4520792. DOI: 10.1136/annrheumdis-2014-206411. View

14.

van Vollenhoven R, Takeuchi T, Pangan A, Friedman A, Mohamed M, Chen S . Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. Arthritis Rheumatol. 2020; 72(10):1607-1620. PMC: 7589375. DOI: 10.1002/art.41384. View

15.

Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J . Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2022; 82(2):189-197. PMC: 9887398. DOI: 10.1136/ard-2022-223050. View

16.

Kramer A, Prinz C, Fichtner F, Fischer A, Thieme V, Grundeis F . Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. 2022; 6:CD015209. PMC: 9190191. DOI: 10.1002/14651858.CD015209. View

17.

Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E . Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2022; 82(2):182-188. DOI: 10.1136/ard-2022-222824. View

18.

Rubbert-Roth A, Enejosa J, Pangan A, Haraoui B, Rischmueller M, Khan N . Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020; 383(16):1511-1521. DOI: 10.1056/NEJMoa2008250. View

19.

Sparks J, Wallace Z, Seet A, Robinson P, Machado P, Yazdany J . Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by van Vollenhoven . Ann Rheum Dis. 2021; 82(8):e178. DOI: 10.1136/annrheumdis-2021-221157. View

20.

Kerschbaumer A, Smolen J, Nash P, Doerner T, Dougados M, Fleischmann R . Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020; 6(3). PMC: 7856126. DOI: 10.1136/rmdopen-2020-001374. View